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Systemic lupus erythematosus is characterized by a breakdown of self-tolerance and production of autoantibodies. Kidney
involvement (i.e., lupus nephritis) is both common and severe and can result in permanent damage within the glomerular,
vascular, and tubulo-interstitial compartments of the kidney, leading to acute or chronic renal failure. Accumulating evidence
shows that anti-dsDNA antibodies play a critical role in the pathogenesis of lupus nephritis through their binding to cell surface
proteins of resident kidney cells, thereby triggering the downstream activation of signaling pathways and the release of mediators
of inflammation and fibrosis. This paper describes the mechanisms through which autoantibodies interact with resident renal cells
and how this interaction plays a part in disease pathogenesis that ultimately leads to structural and functional alterations in lupus
nephritis.
1. Introduction
Lupus nephritis is a severe organ manifestation of systemic
lupus erythematosus (SLE) that can aﬀect up to 70%
of the SLE population [1]. Depending on the severity of
disease, 10–30% of these patients will progress to end-
stage renal failure. Lupus nephritis is characterized by the
production of anti-double-stranded (ds) DNA antibodies
and immune-mediated injury in the glomerular, vascular,
and tubulo-interstitial compartments of the kidney [2–9]. If
left untreated, destruction of the normal renal parenchyma
and their replacement with fibrous tissue ensues [7]. Lupus
nephritis follows a relapsing-remitting pattern in which
the frequency of flares diﬀers between individual patients.
Clinical manifestations of active lupus nephritis include
proteinuria, active urinary sediments, and progressive renal
dysfunction [10, 11].
Anti-dsDNA antibodies have been shown to contribute
to the pathogenesis of lupus nephritis. Many features of lupus
nephritis can be replicated in nonautoimmune mice after
either intraperitoneal administration of human or murine
anti-dsDNA antibodies or inoculation with the transgene
that encodes the secreted form of an IgG anti-DNA antibody
[12, 13]. It has remained intriguing how these antibodies
deposit in the kidneys and trigger intrarenal pathogenic
mechanisms. Various mechanisms of antibody binding have
been proposed, some of which remain controversial. The
origin of anti-dsDNA antibodies, their pathogenic role, and
the characteristics associated with nephritogenic property
have been extensively studied in experimental and in vitro
systems [2, 3, 6, 13–15]. The data to date shows that polyre-
activity and the ability to interact with various cell surface,
intracellular, or extracellular molecules could be a pivotal
property that allows the antibodies to elicit injury in the
kidney [16–19]. This paper will discuss the contributing roles
of resident renal cells in the pathogenesis of lupus nephri-
tis through their interaction with anti-dsDNA antibodies,
thereby inducing inflammatory and fibrotic processes in
the kidney. Mechanisms through which lymphocytes and
macrophages contribute to the pathogenesis of lupus nephri-
tis have been discussed in recent papers [20–22].
1.1. Anti-dsDNAAntibodies and Lupus Nephritis. Production
of autoantibodies is a cardinal feature of SLE [23]. The
production of antibodies towards chromatin material, in
particular to dsDNA, is strongly associated clinically with
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Table 1: Autoantibodies with pathogenic potential in patients with lupus nephritis.
Autoantibodies Prevalence (%)
Binding to kidney
structure/resident renal cells
References
Anti-dsDNA 70–96 GBM [29–31]
Mesangial cells
Glomerular epithelial cells
Glomerular endothelial cells
Proximal tubular epithelial cells
Anti-nucleosome 60–90 GBM [29, 31, 32]
Mesangial cells
Glomerular epithelial cells
Glomerular endothelial cells
Anti-Ro 25–44 GBM [29, 33]
Anti-Smith 10–60 GBM [29, 30, 33]
Anti-C1q 40–97 GBM [29, 31, 34, 35]
Glomerulus
Tubular basement membrane
Anti-α-actinin 20 Glomerulus [16, 17, 29, 36]
Mesangial cells
Podocytes
Anti-annexin II 32–65 Glomerulus [18]
Mesangial cells
Anti-ribosomal P protein 75 Glomerulus [37, 38]
Mesangial cells
lupus nephritis [4–6, 23–28]. Other autoantibodies have also
been described in patients with lupus nephritis [18, 29–38]
and these are listed in Table 1.
Anti-DNA antibodies constitute a subgroup of anti-
nuclear antibodies that bind to either single-stranded or
double-standard DNA [2]. These antibodies form part of the
normal spectrum of natural antibodies in healthy individuals
which are predominantly of the IgM class and react weakly
with self-antigens. In lupus patients, these “natural” anti-
bodies undergo an isotype switch to IgG that increases their
pathogenic potential [2]. Somatic mutations in the encoding
immunoglobulin genes can also result in the secretion of
high-aﬃnity IgG anti-dsDNA antibodies [2, 39]. It is this
subset of anti-dsDNA antibodies that have been implicated
in pathogenesis of SLE and glomerulonephritis. Anti-dsDNA
antibodies of the IgG subclass, in particular those of the IgG1
and IgG3 subclass which can fix complement, are important
in pathogenesis and also as a disease biomarker [2, 40, 41].
Anti-dsDNA antibodies have been detected in the sera of
SLE patients before clinical onset of disease [42], and the
prevalence of anti-dsDNA antibodies in patients with lupus
nephritis is 70–96% compared to 0.5% in patients with
nonlupus autoimmune disease or in healthy subjects [29,
31, 43]. Other factors that determine the nephritogenicity
of anti-DNA antibodies include avidity of antigen binding,
charge, and amino acid sequence in the complementarity
determining region, as reviewed by Foster et al. [8] and
Isenberg et al. [27].
Circulating levels of anti-dsDNA antibodies correlate
with disease activity inmany patients [4, 24, 27, 44].Winfield
et al. demonstrated that the aﬃnity of circulating anti-
dsDNA antibodies to dsDNA correlated with the activity of
nephritis [14]. They also noted that the anti-dsDNA activity
in IgG fractions eluted from nephritic glomeruli was higher
than that in corresponding serum samples [14].
2. Mechanisms through Which Lupus
Autoantibodies Mediate Kidney Injury
Onset of lupus nephritis is initiated by the deposition of anti-
dsDNA antibodies in the renal parenchyma. The exact mech-
anism through which anti-dsDNA antibodies are deposited
in the kidney to mediate kidney injury remains to be fully
elucidated. Three mechanisms have been proposed, and
they include (1) the deposition of preformed circulating
DNA/anti-dsDNA immune complexes in the kidney, (2)
binding of antibodies to antigens deposited within the
kidney—the “planted antigen” theory, and (3) direct binding
to cross-reactive antigens present either on the surface of
resident renal cells or in their extracellular environment.
2.1. Entrapment of Circulating Preformed DNA/Anti-dsDNA
Immune Complexes. It had been postulated that renal injury
in lupus patients was due to the passive entrapment of
circulating preformedDNA/anti-dsDNA immune complexes
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in the glomerulus. This theory has now been disproved
since preformed immune complexes are diﬃcult to detect
in the blood, and studies have demonstrated that they are
only transiently localized to the glomeruli before they are
rapidly removed by the liver [45]. Following administra-
tion to nonautoimmune mice, preformed DNA/anti-dsDNA
immune complexes have no aﬃnity for components of the
glomerular basement membrane (GBM) [46]. Furthermore,
after administration of these immune complexes to lupus-
prone mice, the level of anti-dsDNA antibodies and disease
activity decreased [47].
2.2. “Planted Antigen” Theory. In the “planted antigen” the-
ory, chromatin materials released into the circulation from
apoptotic or necrotic cells are entrapped within the GBM
where they serve as “planted antigens” to mediate binding
of anti-dsDNA antibodies. Studies have suggested that the
positively charged histone component of nucleosomes may
initially bind to heparan sulfate proteoglycans in the GBM
through charge-charge interactions, which exposes the DNA
component of the nucleosome to act as a “planted antigen”
or intermediate bridge for anti-dsDNA antibody binding
[48, 49]. Subsequent studies have corroborated that anti-
dsDNA antibodies can bind to the glomerulus through
nucleosomes [26, 48–50]. Kramers et al. demonstrated
that the perfusion of anti-dsDNA antibodies complexed
to nucleosomal material into Wistar rats resulted in their
deposition in the glomerular capillaries [51]. Subcutaneous
administration of heparin to NZB/W F1 mice resulted in
reduced nucleosome-containing immune complexes in the
GBM and delayed development of disease manifestations
suggesting that heparin may compete with extracellular
heparan sulfate proteoglycans for nucleosome binding,
thereby reducing immune complex formation in the kidney
parenchyma [52]. Ultrastructural studies by Rekvig’s group
have demonstrated that anti-dsDNA antibodies colocalize
with chromatin material in electron-dense deposits in the
diseased kidney [26, 50]. The role of nucleosomes in
the pathogenesis of lupus nephritis has been reviewed by
Mortensen and Rekvig [53]. Anti-nucleosome antibodies
have also been detected in SLE patients particularly in
patients with renal flare [54]. Some have proposed that anti-
nucleosome antibodies may be a disease biomarker for lupus
nephritis [54, 55].
2.3. Cross-Reactivity with Non-DNA Antigens. Autoreactivity
to native DNA per se does not appear to be a property of anti-
dsDNA antibodies that are responsible for inducing renal
injury. Immunization of non-autoimmune mice with mam-
malian DNA failed to induce the production of pathogenic
anti-dsDNA antibodies or clinical manifestations of disease.
Rather, there is emerging evidence that polyreactivity of
anti-dsDNA antibodies, independent of chromatin material
acting as a bridge for binding, confers pathogenic potential.
Polyreactivity of anti-dsDNA antibodies may be related
to structural or conformational similarity, or molecular
mimicry [56]. Cross-reactivity of anti-dsDNA antibodies was
first observed by Raz et al., who demonstrated that human
andmurine anti-DNA antibodies could bind directly to renal
antigens in isolated rat kidneys, and this resulted in the
induction of proteinuria [57]. Krishnan et al. demonstrated
that anti-dsDNA antibodies from lupus-prone mice when
injected intravenously into BALB/c mice could bind to
the GBM and mesangial matrix and induce disease man-
ifestations, and that these processes were independent of
the binding of the antibodies to chromatin material [58].
Waters et al. observed that NZM congenic mice developed
chronic glomerulonephritis in the absence of anti-dsDNA
antibodies [59]. Christensen et al. also noted that nephritis
developed in Toll-like receptor-9- (TLR-9) deficient lupus-
prone mice despite the absence of anti-dsDNA antibodies
[60]. It is thus possible that the reactivity of antibodies
towards DNA or chromatin material per se may not be
critical for the development of lupus nephritis, but rather
the ability of autoantibodies to bind to various antigens in
the renal parenchyma. α-actinin, heparan sulfate proteogly-
can, laminin, fibronectin and collagen have been reported
as putative antigens that are recognized by anti-dsDNA
antibodies [16–18, 61–63]. However, some of the data
were derived from experiments with murine monoclonal
anti-DNA antibodies with uncertain clinical relevance in
human lupus. Also, some studies employed solid-phase
binding assays, which could introduce binding artifacts and
conformational changes to the surface-bound antigens [64],
and therefore, in vitro and experimental studies should be
undertaken to confirm such findings. More recently, our
group showed that human anti-dsDNA antibodies could
bind to annexin II on the surface of human mesangial cells
and induce changes in cell function [18].
3. Anti-dsDNA Antibody Binding to
Kidney Cells and Renal Injury
Renal injury in lupus nephritis is initiated by the depo-
sition of autoantibodies and/or immune complexes in
the renal compartments. Downstream pathogenic eﬀector
mechanisms include activation of the complement and
coagulation cascades, infiltration of acute and chronic
inflammatory cells, and induction of mediators of inflam-
mation or fibrosis from resident kidney cells and infiltrating
cells. Polyclonal B-cell activation and autoantigen-driven
expansion of autoreactive B cells result in the increased
production of polyclonal anti-dsDNA antibodies in lupus
patients and their deposition in sites of injury [65, 66].
Morphologic changes in the kidney are variable as reflected
by the spectrum of pathological changes in lupus nephritis
[67]. Previous studies have demonstrated heterogeneity in
the molecular pathogenesis between patients with lupus
nephritis [68]. Depending on the type, duration, and severity
of lupus nephritis, immune deposits can be found in
the mesangium, subendothelial, subepithelial, and tubulo-
interstitial regions [67]. Deposition of cationic immune
deposits in the mesangial or subendothelial compartments
can initiate the recruitment of inflammatory cells and the
activation of resident mesangial and endothelial cells [56].
Immune deposition in the subepithelial area is associated
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Table 2: Binding of anti-dsDNA antibodies to resident renal cells and the eﬀect on cellular functions.
Mesangial cells Endothelial cells
Proximal renal tubular
epithelial cells
Mechanism of binding Indirect binding through Indirect binding through Indirect binding through
DNA, histones, and nucleosomes DNA, histones, and nucleosomes DNA
Cross-reactive binding to Cross-reactive binding to Cross-reactive binding to
heparan sulfate hevin A and D snRNP proteins
ribosomal P protein unidentified proteins with M.W.
laminin of 30–35, 44, 68, 110, and 180 kDa
α-actinin
annexin II
Internalization of anti-dsDNA Occurs after binding to annexin II Occurs after binding to fibronectin Occurs after binding to
antibodies into resident renal cells unidentified protein(s)
Eﬀect on cell proliferation Increase Increase Increase
Induction of apoptosis Yes Yes Yes
Eﬀect on cell viability Decrease Decrease Decrease
Eﬀect on inflammation Increased synthesis of: Increased synthesis of: Increased synthesis of:
IL-1β, IL-6, and TNF-α IL-1β, IL-6, and IL-8 IL-1β
hyaluronan adhesion molecules IL-6
von Willebrand factor TNF-α
Eﬀect on fibrosis Activation of PKC-α, -βI, Increased gene expression Induced epithelial-to
and βII signaling pathways of TGF-β1 mesenchymal
and increased synthesis of transdiﬀerentiation
TGF-β1 and fibronectin
with podocyte injury and proteinuria, while the GBM acts
as a barrier for leukocyte infiltration [56]. Irrespective of
the site of initial or predominant injury, downstream events
such as deposition of extracellular matrix and renal scarring
constitute a final common pathway.
Data from in vitro studies have demonstrated that anti-
dsDNA antibodies can bind to mesangial cells, glomerular
epithelial cells (podocytes), endothelial cells, and proximal
tubular epithelial cells [4, 5, 69–72], and that such binding
led to functional changes in these cells [5, 18, 72–77]. The
following discussion will focus on the results to date on
the interaction between anti-dsDNA antibodies and resident
renal cells in the context of the pathogenesis of lupus
nephritis (Table 2).
3.1. Anti-DNA Antibodies and Mesangial Cells. Mesangial
cells constitute up to 40% of the total cells in the glomerulus
and are situated centrally within the glomerulus [78]. They
are contractile and have morphological and functional
properties similar to smooth muscle cells. Mesangial cells are
able to synthesize a plethora of cytokines, growth factors, and
matrix proteins which, together with their contractile prop-
erty, provide structural support to the capillary loops and
contribute to kidney homeostasis. Mesangial cells contribute
to the synthesis and remodeling of extracellular matrix,
which together with the cells constitute the mesangium.
Qualitative and quantitative changes to the mesangial matrix
can have a profound eﬀect on mesangial cell function and
behavior [78, 79]. As a corollary, these properties also explain
the pathophysiology that follows mesangial cell injury.
Deposition of immunoglobulins and activation of com-
plement within the mesangium is a cardinal feature in lupus
nephritis, while complement activation plays an important
role in the pathogenesis of diﬀerent types of glomerular
diseases [80]. Fenton et al. demonstrated that deposition of
immune complexes in the mesangium of NZB/W F1 mice
during the early phase of disease was accompanied by the
appearance of anti-dsDNA antibodies, which preceded the
downregulation of DNase 1 mRNA and activity [81]. In
this regard, reduced renal expression of DNase 1 in lupus-
prone mice is thought to be a mechanism for reduced
fragmentation and clearance of chromatin material [53].
There is evidence that mesangial cells can synthesize C3,
which is increased when the cells are incubated with immune
complexes [82]. Mesangial cells thus have the potential to
contribute to complement activation in the kidney and to
complement-mediated injury in the mesangium.
The administration of anti-dsDNA antibodies to either
predisease NZB/W F1 or BALB/c mice results in their depo-
sition in the glomerulus, including the mesangium, through
indirect chromatin-mediated or direct cross-reactive binding
[13, 18, 83]. We and others have demonstrated that anti-
dsDNA antibodies can bind to mesangial cells through
chromatin material [69] or through the direct interaction
with cross-reactive antigens such as α-actinin, annexin II,
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or ribosomal P protein, and that such binding may or may
not be dependent on the Fc portion [16–18, 38, 84]. The
functional consequences of this interaction include increased
mesangial proliferation, apoptosis, activation of the PKC
and MAPK signaling pathways, and increased synthesis of
proinflammatory cytokines and profibrotic mediators such
as hyaluronan, IL-1β, IL-6, TNF-α, TGF-β1, and fibronectin
[18, 28, 72, 75, 76, 84–86].
The data that α-actinin can mediate the binding of anti-
dsDNA antibodies to mesangial cells is intriguing, since
α-actinin is an intracellular constituent of the mesangial
cytoskeleton. α-actinin is present in multiple subcellular
regions such as cell-cell and cell-matrix contact sites, in
addition to cellular protrusions and lamellipodia [87, 88].
It is thus possible that part of the α-actinin molecule
may extrude through the plasma membrane of mesangial
cells to permit its binding with anti-dsDNA antibodies,
although this needs to be confirmed by further studies.
We have previously demonstrated that α-actinin expression
is increased within the mesangium of patients with pro-
liferative renal diseases [88]. Consistent with our finding,
Zhao et al. also observed increased α-actinin expression in
mesangial cells isolated from MRL/lpr mice [89], thereby
suggesting increased availability of α-actinin for anti-dsDNA
antibody binding. The pathogenic role of α-actinin as a
cross-reactive antigen has recently been questioned by Mjelle
et al. who demonstrated that anti-dsDNA antibodies did
not colocalize with α-actinin in kidneys obtained from
NZB/W F1 mice, but instead bound to glomerular structures
containing extracellular nucleosomes [90].
Annexin II is a calcium-dependent, phospholipid bind-
ing protein that is expressed in various organs including
the kidney and can exist either as a monomer, heterodimer,
or heterotetramer [91]. Annexin II is present within the
cytoplasm and on the plasma membrane of various cells
[91], and its translocation from the cytoplasm to the plasma
membrane is increased following its phosphorylation that
can be induced by various cytokines and growth factors
such as IFGF and EGF or heat stress [92, 93]. It functions
as a plasminogen receptor, thus regulating fibrin homeosta-
sis and angiogenesis and also membrane traﬃcking [94].
Autoantibodies to annexin II are detected in patients with
antiphospholipid syndrome, and annexin II has been shown
to activate endothelial cells following their exposure to
antiphospholipid antibodies [95]. We have recently demon-
strated that annexin II is a cross-reactive antigen on the
surface of humanmesangial cells thatmediates the binding of
human polyclonal anti-dsDNA antibodies [18]. We further
demonstrated that following the binding of anti-dsDNA
antibodies to annexin II, the antibodies were internalized and
translocated to the cytoplasm and nucleus in a time- and
temperature-dependent manner [18]. The ability of anti-
dsDNA antibodies to penetrate live cells was first observed by
Alarcon-Segovia and Llorente in human mononuclear cells
[96], and subsequently by Yanase et al. in rat H35 hepatoma
cells [97, 98]. It is noteworthy that entry of antibodies into
cells is not unique to anti-dsDNA antibodies, since this
phenomenon has also been observed with autoantibodies
against nuclear ribonucleoprotein, ribosomal P protein, La,
and Ro in human and animal cells [99–102].
Data from our laboratory showed that binding of anti-
dsDNA antibodies to annexin II on mesangial cell surface
induced annexin II synthesis in the cells, and the latter
was mediated through the activation of p38 MAPK, JNK,
and AKT/PI3K signaling pathways. There was also a con-
comitant increase in cell proliferation, induction of IL-
1β, TNF-α, IL-6, and hyaluronan secretion, activation of
the PKC signaling pathway, and upregulation of TGF-β1
and fibronectin synthesis [18, 75, 76]. These findings thus
propose a new paradigm by which anti-dsDNA antibodies
contribute to progressive inflammatory and fibrotic pro-
cesses in the pathogenesis of lupus nephritis. The eﬀect
on IL-6 is worth highlighting, since this cytokine has been
shown to increase mesangial cell proliferation and exacerbate
glomerulonephritis [103]. Our results from animal experi-
ments and human renal biopsies also showed that annexin
II expression was increased in the mesangium and GBM of
NZB/W F1mice and patients with active lupus nephritis, and
it colocalized with IgG and C3 deposition [18]. Intercepting
the interaction between anti-dsDNA antibodies and annexin
II on mesangial cells may therefore be a potential novel
approach for the treatment of lupus nephritis.
The mechanism(s) through which autoantibodies are
internalized, and the functional consequence of this process,
have yet to be fully elucidated, but it has been suggested that
some of these autoantibodies may be internalized through
an Fc receptor-dependent mechanism, which was associated
with cellular changes such as cytotoxicity and apoptosis
[104]. Internalization and nuclear localization of anti-
dsDNA antibodies may also be dependent on their polyre-
activity and the presence of nuclear localizing motifs in the
CDR3 region of the heavy chain [105]. It is possible that these
autoantibodies are transported intracellularly via clathrin-
associated vesicles or are accompanied by chaperones [106].
The administration of murine anti-dsDNA antibodies to
non-autoimmune mice resulted in their localization in the
cell nuclei of many organs including the kidney, and this
was associated with glomerular hypercellularity, increased
collagen expression in the mesangial matrix, and proteinuria
[107]. However, cellular entry and localization of these anti-
dsDNA antibodies were shown to be dependent on the
antigen-binding region of the molecule but not mediated
through the Fc-receptor, although the role of Fc-mediated
inflammation in the mesangium through other pathways
cannot be excluded [107, 108].
3.2. Anti-DNA Antibodies and Endothelial Cells. The glom-
erular capillary endothelium diﬀers from other endothelial
cells in that they are flattened and highly fenestrated [109].
Endothelial cell activation and injury is a common occur-
rence in various immune-mediated glomerular diseases
where there is complement activation in the subendothelial
space, as observed in severe proliferative lupus nephritis
[67, 110]. Activation of glomerular endothelial cells results in
the upregulation of adhesion molecules [111], which serves
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to stabilize the adhesion of infiltrating leukocytes to the sub-
endothelial andmesangial regions during immune-mediated
renal injury.
Anti-endothelial cell antibodies have been detected in
the serum of a high proportion of lupus patients, especially
during active disease [112–118]. Serum levels of anti-
endothelial cell antibodies correlate with the severity of lupus
nephritis and serological evidence of endothelial dysfunction
[116, 119]. Anti-endothelial cell antibodies have also been
shown to induce glomerulonephritis in normal rabbits [120].
Fujii et al. observed that intraperitoneal injection of 17H8a,
a hybridoma clone derived from MRL/lpr mice, into SCID
mice resulted in the deposition of 17H8a antibodies in the
subendothelium and the formation of glomerular lesions
similar to those in lupus-prone mice [121]. Furthermore, the
17H8a antibodies could be internalized by human umbilical
vein endothelial cells (HUVECs) and glomerular endothelial
cells through a mechanism that was mediated by fibronectin
and actin polymerization [121]. It was not reported whether
17H8a antibodies were reactive towards dsDNA.
Subsets of murine monoclonal anti-dsDNA antibodies
can bind to HUVEC indirectly through chromatin material,
indicating that anti-dsDNA antibodies contribute to the
repertoire of anti-endothelial cell antibodies [69, 70, 117].
We have previously reported that, in the presence of DNA,
some murine anti-dsDNA antibodies are able to bind to an
HUVEC plasma membrane protein with an M.W. of 46 kDa,
and the ability of DNA to bind to the surface of HUVEC was
increased in the presence of IL-1α or TNF-α [70]. Histones
could also facilitate the binding of murine monoclonal anti-
dsDNA antibodies and DNA to HUVEC, and the degree
of binding was influenced by the relative concentrations of
antibody, DNA, and histones [69]. In the human setting,
polyclonal anti-dsDNA antibodies isolated from diﬀerent
patients with lupus nephritis could bind to HUVEC through
two distinct mechanisms. Human polyclonal anti-dsDNA
antibodies that required DNA to bind to HUVEC also
bound to a protein of M.W. 46 kDa, whereas direct cross-
reactive binding was mediated through membrane proteins
with M.W. of 30–35, 44, 68, 110, and 180 kDa [122].
Incubation of HUVEC with human polyclonal anti-dsDNA
antibodies induced the expression of VCAM-1, ICAM-1, and
von Willebrand factor, which was associated with increased
expression of IL-1, IL-6, and IL-8, which had been shown
to play an important role in the inflammatory processes in
lupus nephritis [73, 74, 123, 124].
Accumulating evidence suggests that type I interferons
(IFN) such as IFN-α and IFN-γ play an important role
in the pathogenesis of lupus nephritis [125, 126]. These
proinflammatory peptides are synthesized by both infiltrat-
ing and resident renal cells including glomerular endothelial
cells [127]. Recent studies have demonstrated that type
I IFN synthesized by resident renal cells promoted end-
organ disease in an experimental model of autoantibody-
mediated glomerulonephritis [128]. It is possible that anti-
dsDNA antibodies may also induce synthesis of IFN-α and
IFN-γ in endothelial cells and other intrinsic renal cells
to mediate downstream inflammatory processes although
further studies are warranted to confirm this.
3.3. Anti-DNAAntibodies and Proximal Renal Tubular Epithe-
lial Cells. Approximately 70% of lupus nephritis patients
have demonstrable immune aggregates along the renal tubu-
lar basement membrane. The tubulo-interstitium occupies
up to 90% of the kidney volume. Variable degrees of tubulo-
interstitial inflammation and fibrosis are found in practically
all forms of chronic progressive renal diseases regardless
of the inciting injury, including those which start oﬀ as
a predominantly glomerular disease, and the severity of
tubulo-interstitial changes inversely correlates with renal
prognosis [129, 130]. Proximal renal tubular epithelial
cells constitute the predominant cell type in the tubulo-
interstitium. These cells are responsible for solute transport
and reabsorption. They have the ability to synthesize growth
factors and matrix proteins and have a high proliferative
potential and thus are important in the regeneration of the
tubular epithelium in response to acute tubular injury. Upon
stimulation by proinflammatory or profibrotic mediators,
proximal renal tubular epithelial cells exhibit phenotypic
alterations and undergo epithelial-to-mesenchymal transd-
iﬀerentiation (EMT) [131]. EMT is characterized by the
loss of epithelial cell adhesion, cell activation with actin
reorganization and de novo synthesis of α-smooth muscle
actin, disruption of the underlying basement membrane,
and increased cell migration and invasion [132–134]. There
is compelling evidence that the presence of myofibroblasts
predicts progressive fibrosis in animal and human renal
diseases [135–140].
We have demonstrated that the deposition of immune
complexes in the tubulo-interstitium correlated with circu-
lating anti-dsDNA antibody levels, tubulo-interstitial expres-
sion of IL-6, and tubulo-interstitial abnormalities that
included tubular atrophy, inflammatory cell infiltration, and
interstitial fibrosis [5]. The level of tubulo-interstitial IL-
6 expression, predominantly contributed by the proximal
tubular epithelial cells, correlated with the infiltration of
immune cells into the tubulo-interstitium.
HK-2 cells are normal proximal renal tubular epithelial
cells that have been immortalized by transduction with the
human papilloma virus [141]. We have demonstrated that
anti-dsDNA antibodies from patients with lupus nephritis
induced phenotypic changes in HK-2 cells that were analo-
gous to epithelial cells undergoing EMT [5]. We have also
demonstrated that anti-dsDNA antibodies, especially those
derived from patients during active disease, could induce
IL-6 secretion in HK-2 cells [5]. Depending on the disease
status, the induction of IL-6 secretion in HK-2 cells by
anti-dsDNA antibodies can be through distinct mechanisms.
During remission, anti-dsDNA antibodies induced IL-6
secretion either directly or were mediated through IL-1β.
In contrast, anti-dsDNA antibodies isolated from patients
with active disease induced IL-6 secretion through the prior
induction of both IL-1β and TNF-α [5]. The heterogeneity
may be related to distinct properties of diﬀerent clones of
anti-dsDNA antibodies. Mediators secreted by mesangial
cells and HK-2 cells upon stimulation with anti-dsDNA
antibodies can induce IL-6 secretion in the other cell types,
indicating that there could be bidirectional communication
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or crosstalk between the glomerulus and tubulo-interstitium
[5]. Consistent with our findings, Ronda et al. also observed
that immunoglobulins isolated from the sera of patients with
SLE could induce IL-6 secretion in proximal renal tubular
epithelial cells, and this was accompanied by the activation
of the ERK signaling pathway [142].
Koren et al. have reported that murine and human
anti-dsDNA antibodies cross-reacted with A and D snRNP
proteins in porcine proximal tubular epithelial cells (PK15
cells). Of the two murine monoclonal antibodies tested
that were derived from NZB/W F1 mice, one anti-dsDNA
antibody was internalized and localized in the cytoplasm and
nuclei of cells, while the secondmurinemonoclonal antibody
remained at the cell surface and was not internalized. The
concomitant addition of complement and either murine or
human anti-dsDNA antibodies to PK15 cells resulted in cell
lysis, which was more prominent with the subset of anti-
dsDNA antibodies that were not internalized [143]. Zack
et al. demonstrated that the murine anti-dsDNA antibody
mAb 3E10 could bind to renal tubules in normal human
renal tissue, and intraperitoneal injection of mAb 3E10
into normal BALB/c mice primed with pristane resulted in
antibody binding to the plasma membrane of proximal renal
tubular epithelial cells and their subsequent internalization
and translocation into the nucleus [71]. This binding was
dependent on DNA and the Fab portion of the antibody
[71]. These studies have thus begun to shed light on the
pathogenic pathways through which anti-dsDNA antibodies
can induce tubulo-interstitial injury through their interac-
tion with proximal renal tubular epithelial cells.
3.4. Anti-DNA Antibodies and Podocytes. Podocytes are
highly diﬀerentiated epithelial cells that are found on the
outer surface of the glomerular capillary tuft and serve as
the final barrier to urinary protein loss by the formation
of foot processes and interposed slit diaphragms [144]. We
and others have demonstrated that anti-dsDNA antibodies
can bind to podocytes in vitro and in vivo [4, 90, 145]. The
administration of a human monoclonal anti-dsDNA/anti-α-
actinin antibody to SCID mice resulted in their subepithelial
and subendothelial deposition, which was associated with
widespread, segmental eﬀacement of podocyte foot processes
and proteinuria [145]. Although it is tempting to speculate
that anti-dsDNA antibodies may bind to podocytes through
α-actinin, studies by Mjelle et al. suggest otherwise [90].
These researchers proposed that nucleosomes mediated the
binding of anti-dsDNA antibodies to glomerular structures
in vivo [90]. Subepithelial immune deposits along the
peripheral capillary loops is a cardinal feature in patients
with class V lupus nephritis, which results in podocyte
hypertrophy, their increased synthesis of matrix proteins,
and subsequent thickening of the GBM [146].
4. The Role of Toll-Like Receptors in
the Pathogenesis of Lupus Nephritis
TLRs are a class of innate immune receptors that regulate
inflammatory and immune responses. They are essential
for the induction of adaptive immune responses against
microbial infection [147]. Although they are predominantly
expressed on leukocytes, resident renal cells also express
distinct members of the TLR family depending on the
cell type [148]. Accumulating evidence suggests that TLRs
contribute to the pathogenesis of lupus nephritis, where
nonmicrobial, host-derived nucleic acids activate TLRs
and exacerbate disease manifestations [149–151]. TLR-9
recognizes hypomethylated CpG-containing DNA motifs
including those of mammalian origin released from injured
or stress-induced cells [149, 152]. Activation of TLR-9 by
DNA-containing immune complexes is mediated through
high-mobility group box proteins and receptor for advanced
glycation end-products [149], and once activated, it aug-
ments cytokine production in dendritic cells [149, 153].
TLR-9 activation also regulates the production of anti-
dsDNA antibodies in lupus-prone mice [60, 154]. The
expression of TLR-9 in resident renal cells is arguable
since some researchers have shown TLR-9 to localize solely
on infiltrating cells [155], whilst other researchers have
observed increased TLR-9 expression in tubular epithelial
cells and glomerular cells during active lupus nephritis [156,
157]. Increased tubular expression of TLR-9 correlates with
proteinuria and tubulo-interstitial injury in lupus patients,
whereas increased glomerular TLR-9 expression is associated
with a higher activity index [156, 157]. Inhibition of TLR-
9 signaling in lupus-prone mice attenuates the development
of glomerulonephritis [158] although its pathogenic role
in the development of lupus nephritis has recently been
questioned [159]. Mesangial and tubular epithelial cells also
express TLR1-4 and TLR-6 [148, 155], but their role in the
pathogenesis of lupus nephritis remains to be defined.
5. Conclusion
Renal involvement is a major cause of morbidity and mor-
tality in SLE. Pathological manifestations in lupus nephritis
are diverse, initiated by the deposition of immunoglobulins
and formation of immune complexes in the glomerular
and tubulo-interstitial compartments of the kidney. There is
emerging evidence that the interaction between anti-dsDNA
antibodies and resident kidney cells, notably mesangial
cells, proximal renal tubular epithelial cells, glomerular
endothelial cells, and possibly podocytes, plays a significant
role in disease pathogenesis. Cell surface binding followed
by translocation of antibodies to the cytoplasm and/or
nucleus precedes the induction of proinflammatory and
profibrotic pathways. Distinct mechanisms may apply to
diﬀerent subsets of antibodies, and at diﬀerent phases of
disease. Not only does the elucidation of these processes
provide researchers with a better understanding of the role
of anti-dsDNA antibodies in pathogenesis, but also it oﬀers
potential novel approaches for disease intervention.
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